GlycoMimetics Inc expected to post a loss of 31 cents a share - Earnings Preview

Crescent Biopharma

03/08/2021 16:46

* GlycoMimetics Inc  GLYC.OQ   GLYC.O  is expected to show a no
change in quarterly revenue when it reports results on August
5. 
​* Refinitiv's mean analyst estimate for GlycoMimetics Inc is
for a loss of 31 cents per share. For the same quarter last
year, the company reported a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for GlycoMimetics
Inc is $14​, about 85.6% above​ its last closing price
of $2.01. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.31       -0.32      -0.28     Beat    12
 Dec. 31 2020  -0.32       -0.32      -0.32     Met     0.6
 Sep. 30 2020  -0.33       -0.33      -0.29     Beat    11.6​
 Jun. 30 2020  -0.38       -0.38      -0.32     Beat    15.8
 Mar.          -0.30​      -0.30      -0.18     Beat    40.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.35       -0.35      -0.34     Beat    1.9​
 Sep. 30 2019  -0.40       -0.39      -0.31     Beat    20.9
 Jun. 30 2019  -0.37       -0.36      -0.37     Missed  -1.8
 This summary was machine generated August 3 at 15:46 GMT.  All
figures in US dollars unless otherwise stated